TMCI

Content Detail

Content META

Title	Treace Medical at UBS Global Healthcare: Navigating Market Challenges
ID	27788752
External ID	d93478430d4c0caf6976946b51334885
Author
Published Date	Nov. 10, 2025, 5:16 p.m.
Summary	Treace Medical at UBS Global Healthcare: Navigating Market Challenges
Tags
URL	https://www.investing.com/news/transcripts/treace-medical-at-ubs-global-healthcare-navigating-market-challenges-93ch-4347908
Sentiment	Negative: 0.06652 Neutral: 0.07780 Positive: 0.85568
Relevance	0.03986

Content Details

Content ID	35471142
Key	4b6b9af4-9e31-4c96-9e89-488c0f601a30
Content	On Monday, 10 November 2025, Treace Medical Concepts Inc (NASDAQ:TMCI) presented at the UBS Global Healthcare Conference 2025, addressing both strategic opportunities and current challenges. CEO John Truth and CFO Mark Harris outlined a mixed performance landscape, highlighting the company's efforts to adapt to market shifts and bolster growth amid softer demand for its flagship lapoplasty bunion correction system. Key Takeaways Treace Medical is expanding its bunion treatment portfolio to address a broader market. The company achieved over $200 million in annual revenue, primarily from lapoplasty. Despite demand softness, Treace is focusing on new product launches and surgeon training. Financial strategies include maintaining high gross margins and reducing cash burn by 45%. AI technology, such as IntelliGuide, is being integrated to improve patient-specific diagnostics. Financial Results Revenue: Over $200 million annually, driven by lapoplasty technology. Demand Softness: Affected by interest in minimally invasive osteotomy and patient deferrals. ASP Dynamics: New products have a lower average selling price, impacting revenue growth. Gross Margins: Maintained in the high 70% range, with a slight increase expected in Q4. Cash Burn Reduction: Achieved a 45% reduction compared to the previous year. Operational Updates Product Portfolio Expansion: New solutions for various bunion categories, including mild to severe cases. Surgeon Customer Base: Currently, lapoplasty is used for 25% of bunions, indicating growth potential. New Product Adoption: 20% of customers have adopted new technologies. Training Programs: High demand for training events to introduce new and existing products. Minimally Invasive Solutions: Developed systems for quicker adoption by surgeons. Future Outlook Market Penetration: Targeting four distinct market areas with specialized solutions. Product Launches: Plans for new compression screw systems and Speed Plate technology. Sales Force Expansion: Hiring experienced foot and ankle sales representatives. ASC Setting: Leveraging increased reimbursement for LAPIDUS fusion codes. AI Integration: Using IntelliGuide for enhanced patient-specific instrumentation. Q&A Highlights Market Trends: Addressed patient deferrals and a 7% decline in surgeon volumes year-to-date. Total Addressable Market: Reaffirmed a $5 billion US market with 450,000 procedures annually. Competitive Moat: Focus on innovation, patent position, and surgeon outcomes. Guidance: Awaiting Q4 results to provide 2026 guidance. Clinical Data: Invested in studies demonstrating lapoplasty effectiveness with 4- and 5-year results. In conclusion, Treace Medical remains focused on navigating current market dynamics and leveraging its innovative portfolio for sustainable growth in the bunion treatment space. Readers are encouraged to refer to the full transcript for detailed insights. Full transcript - UBS Global Healthcare Conference 2025: Priya Sotjeba, Med Tech Analyst, UBS: Still morning a little bit, but, welcome to the UBS health care conference day one. And happy to introduce Truth Medical with us here today. We have, John Truth, CEO and Mark Harris, CFO. I'm Priya Sotjeba, one of the med tech analysts here at UBS, and looking forward to a great conversation with you guys. John Truth, CEO, Truth Medical: Sounds great. Thanks, Priya. Great to be here in this beautiful location. We love your meetings. They're always in great spots. Priya Sotjeba, Med Tech Analyst, UBS: Nice spots and not too far for you guys at least. But, yeah, maybe just to kick off, we can give a little bit of an overview of Therese and, you know, your guys' product offering. John Truth, CEO, Truth Medical: Sure. Therese Medical was founded and developed the lapoplasty bunion correction system. We've been advancing that technology for the past ten years. We've achieved over $200,000,000 in annual revenue based largely on that platform technology. And now we're in a transformative phase where we're developing new solutions for different types of abundant indications, and we can talk a little bit more about that. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. Maybe a good segue from there is just talking about current portfolio and some of your new innovations and offerings and how that's filling the gap for for surgeons versus products on the market today. John Truth, CEO, Truth Medical: Sure. And and we, over the past several years, started looking at bunions and looking at the sort of four different categories of bunions and diving deep into those with our surgeon design team and our engineers in developing solutions that could put more focus on those four different areas. If you think about lapoplasty's position in the market, it was this broadly versatile technology that could apply to a wide range of bunion deformities. And what we found over time was many surgeons would adopt that technology for the vast majority of their bunions. Others would adopt it for a partial or a portion of their bunions. And if you look at our 3,100 surgeon customers, the average user uses a lap of plastic on about 25 of their bunions, we estimate. So that means there's seventy five percent of bunions we're not getting to with our current solutions. So the four categories of bunions that we looked at, we've got the mild to moderate bunions. We've got the moderate or more severe bunions. We have bunions that have a midfoot deformity component to them, and then we have bunions with with great toe joint arthritis. So the goal was how do we how do we get after faster penetration into those four distinct market areas? We knew lapoplasty could serve the broad group, but most surgeons kind of decided to put lapoplasty more towards the severe side of bunions. And so we said, let's get after the more mild to moderate bunions more aggressively. So to do that, we designed two minimally invasive osteotomy solutions. These are best in class instrumented systems that can be quickly adopted in the surgeon's practice. And it solves a big challenge with current minimally invasive osteotomy solutions. Osteotomies are 70% of the procedure market today, and so it's the largest volume segment that we're not diving deep into. So surgeons struggle with minimally invasive osteotomies today. We developed two great solutions for this market. Then there's then there's the part of the market that's the big toe fusion market. The big toe fusion market represents about twenty percent of overall bunions, we estimate. We've had no product solution for that category. Now we do with our SpeedMTP bunion, great toe fusion system. So as we take a step back, now we're well equipped to go after all four categories with targeted specialized solutions and dive deeper into seventy five percent of cases that we're not getting to today. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. I want to jump in and kinda talk about how we drive that penetration higher and and, you know, how these products are bringing a new offering and all the innovations. But I I think before we get there, you guys did report earnings last week. Would love to just maybe level set kind of the dynamics you saw in the quarter that, you know, prompted the guidance lower and things like that. Just help us parse through all the all those dynamics and, you know, where to from here. John Truth, CEO, Truth Medical: Sure. You know, we we, we were a little surprised as we got into the quarter, seeing continued softness Yeah. In in demand for lapoplasty. And really, really the driver, that's just more more interest around these minimally invasive osteotomy solutions. So as we went through the quarter, we saw that shifting, and we also had an underlying softness in the relative patient demand market. So when you cast that forward, we saw it through the summer. We saw it through September. We saw it in October. And by October, we had to decide we're just not we're not tracking at the same rate. So we had to make an adjustment and take down our number for q four. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. I mean, I know it's hard to kind of take out that crystal ball and think about, you know, market sentiment and where to from here. But if you could maybe compare to historical periods of, you know, some type of market weakness or a change in patient appetite, you know, what do we need to see to kind of move forward? And how are the new product offerings kind of helping us to also move forward from that? John Truth, CEO, Truth Medical: Yeah. I think I think we're we're seeing some really good underlying, signs of vitality. Like, in q three, we had more, mid single digit bunion procedure volume growth. That was great to see despite, you know, relatively flat revenue growth if you exclude that stock distributor stocking order we had in the quarter. That was encouraging, and we continue to see that volume increasing as we go through October and and into into q four. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. And I know that there is a little bit of an ASP dynamic that's kind of offsetting Right? So maybe just trying to understand, you know, at what point do we reach when do the curves cross to to start moving beyond that headwind? And, maybe walk us through that. Because mid single digit growth is very encouraging. But John Truth, CEO, Truth Medical: Yes. It is. And and we're we're learning through q four. We're gonna need to get through this quarter and see how this mix shift occurs. The newer procedures and products are at a lower, average selling price than our lapoplasty. So that's putting that dampening on it that I mentioned that we continue to see during q three and into early q four. So we're gonna need to see that play out. But, you know, today, we have 20% of our current customer base that's adopted one or more of our new technologies. So we're seeing traction with our existing base of surgeons. It's just now we want to train these surgeons, get them more up to speed on our new products, and get more of them using one, two, or three of our new technologies into their practice. So we can go from that 25% to 50% of their practice over time or or more. That's what we're that's what we're focused on doing. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. Can we talk about utilization maybe between those maybe the newer physicians that are adopting versus existing accounts that are now getting new products? Like, what are we seeing from a difference in growth within these two, you know, subsegments of of your user base? John Truth, CEO, Truth Medical: Well, we're seeing a couple of things. We've got the existing surgeons that are adopting new procedures, which is which is great to see. We're also seeing new surgeons come on board, to Trace Medical because the but is traditionally is a lapis fusion company, and they weren't really that much into lapis fusion. Now we have these new bunion technologies that are more appealing to them. So we are bringing on some of those into the fold. They're adopting our new products, and we're finding some of them are actually adopting our legacy lapoplasty and adductoplastic products too. They're just not adopting those at a rate that's fast enough to make up for the softness on the other side with lapoplasty right now. Priya Sotjeba, Med Tech Analyst, UBS: Got it. When you think about a high volume account, what does that look like from a growth perspective? And maybe early feedback that you're hearing from these accounts that have high utilization. John Truth, CEO, Truth Medical: It's it's it's still a little too early to tell. Okay. We're watching the mix shift in these procedures, and we certainly know today we have certain groups that are doing more volume with us than they were before. But we need to let this play out another quarter. Q three was our first quarter of having this full portfolio fully available, and we learned something there. And we're learning more in q four, and we'll have better details around that as we go forward. Priya Sotjeba, Med Tech Analyst, UBS: Got it. Maybe just at a high level, like, what are surgeons saying today that they're using new products? You know, what are we hearing from a benefit perspective? And I think another dynamic that's interesting is it seems like from our checks, like, training is a little bit easier too with with the new product offering. So we could talk about that and what that's contributing to growth as well. Yeah. John Truth, CEO, Truth Medical: We've had very strong demand for our Bunyan masters training events. This is where the surgeons get introduced to not only our existing, but the new products as well. And the response of these products is absolutely fantastic. Surgeons are recognizing how easy they are to use relative to traditional minimally invasive osteotomy solutions. Traditional minimally invasive osteotomy solutions can take 40 to 50 cases to get up to speed with. We've got systems that they can go do in a lab and go do a couple or three or four cases and be up the learning curve and comfortable doing it in their practice. So the response we're getting from surgeons and the uptake we're getting on these new products is is great. It just it just needs to happen faster so that we can overcome the the ASP difference between a lapoplasty case and these new products. Priya Sotjeba, Med Tech Analyst, UBS: What drives that, you know, the time frame? Or, you know, how do we get over the barriers that are still existent today, you know, from a from a market perspective and then from a trace perspective? John Truth, CEO, Truth Medical: I think from a market perspective, you know, we continue to we continue to train these surgeons and get them using these new products. We, reinforce our sales team and continue to build upon that. And then we also launch additional products that can tap other adjacencies and add procedural volume. We've got a a couple nice new products coming out next year. We've got a new compression screw system that's gonna give our sales reps a more fortified portfolio around the surgeons. And then we have a lot of plastic lightning and new forms of our speed plate technology that will continue to feed and fuel that growth around that that surgeon as a customer. Priya Sotjeba, Med Tech Analyst, UBS: Got it. When you think about the competitive moat for Trace, you have all these great innovations coming to market next year. You know, how do we think about Trace versus competition today, and how is the Salesforce kind of utilizing that when they're on the ground? John Truth, CEO, Truth Medical: Yeah. It's we we obviously have a pretty strong patent position broad and deep in our lapoplasty technology. We continue to file patents in in on our other technologies. We are enforcing our patents. We've been actively doing that out there. But, you know, our big advantage and our best defense is a really strong offense, and it's our rapid innovation. We don't pick a lot of products to get involved in. We pick a few. But the few we pick, we design them really, really well so that surgeons will really appreciate them. And then we spend time training them properly on them so they feel confident with them. And we send in the clinical specialist for their first cases, and then they're handed off to a sales rep that's highly experienced in these products. So what we're known for is really caring about the surgeon's experience and outcomes once they embrace our products. And I think if we continue to do that and be faster and better, that's gonna play well for us long term. Priya Sotjeba, Med Tech Analyst, UBS: Got it. Thinking about your guidance for for next for this quarter, just thinking about as we head into 2026. I know not asking for guidance. I would love if you could give it to us today, but, just a run rate in terms of a market perspective. You know, how should we be thinking about what upside to 2026 could look like or maybe the drivers and tailwinds of potential upside to where the street is in terms of numbers today? Mark Harris, CFO, Truth Medical: And and maybe I'll start, and and John can add a little bit to it. I think it's a great question. And and we we talked a little bit about it last week on our call that as we were watching and observing this nice uptake on our new products, we did have case volume increases. And that's what drives the underlying business. So I think that is strong, and we're very encouraged by that. Some of that momentum that we saw in third quarter is is it's early days in Q4, but we saw that same momentum coming into Q4 and and in some respects, even increasing. So so we want to to feel that. We believe that our surgeons are, in fact, adopting these these these new products. And and we're also, just like John said, we're we're bringing in new surgeons that really hadn't been focused as Trice Medical as their solution to Bunion products. So we're bringing in new surgeons. We're providing new products to our existing surgeon base. And so we we need to get through, this quarter as we learn about this this mixed dynamic. But but at least what we view is very fundamental momentum in the overall penetration. And maybe for a short period of time, we're gonna have this penetration growth rate outpace our revenue growth rate because of this mix shift, and and we're selling some new products at at lower prices. Yeah. I mean now, we're not really talking about 2026. It's it's we've had, you know, the full complement of all of our expanded portfolio really started in July. So we're, you know, four or five months into it. We're learning a lot in q three. We're learning a lot more in q four. This is our largest volume quarter out of every year. It's in q four. So we'll be a lot more informed as we come out of the quarter. And then when we have the fourth quarter earnings call, we'll we'll be better prepared to talk about how we see Priya Sotjeba, Med Tech Analyst, UBS: the dynamics in '26. Understood. I wanna maybe pick apart that penetration dynamic in the total addressable market. You know, how is that shifting with in terms of the TAM with these new product offerings? And maybe give us a refresher on on what the total addressable market is and penetration today and where it can go. John Truth, CEO, Truth Medical: Yeah. We we we've we've talked about the 1,100,000, symptomatic surgical candidates as the base and 450,000 procedures being performed, the $5,000,000,000 US TAM, 2.3 on the procedures. We're gonna be learning. We're not we're not saying the TAM has has shifted at this point in time. We base that off of an average $5,000 selling price, at a certain point in time, and we're gonna see how this mix shifts. If we need to update the TAM based on that as we go into next year, we will. But for now, we, you we see it pretty stable. It's a big market. These patients aren't going away. You know, they they have a chance to decide if they wanna have their surgery within a given year or or wait till the next year, and and try to try to delay it a little bit. And we saw some of that this year, And it and it was surprisingly chronic throughout the year, and it lingered into q four as well. And it was one of the reasons that, you know, we had we had to take our our number down. So the market's still there. The patient base is still there. Four Four and a half million Americans, we estimate, still seek medical attention for their bunion pain every year. Four hundred fifty thousand, we estimate, are getting surgery. But the market's not going away. We view LAPIDUS as about 30% of that overall market, and our penetration in that market is is pretty strong. We're we're probably the lead share player in the LAPIDUS market, single company player. So LAPIDUS has strong preferences from some surgeons, and there are defined indications where every surgeon needs to continue to do a LAPIDUS. And that's why we're gonna continue to invest with Lapoplasty Lightning and other innovations in that space. It's where we started from. We're the lead innovator there, and we're gonna continue to to address that market. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. I mean, I think it's interesting. You know, the patients are still there. Right? And so what are you seeing from, like, is it a delay because of financial incentives? Like, in this era of the big beautiful bill, you know, are people just kind of wait and see? Do physicians have a backlog? You know, trying to understand the appetite here and how that shifts. John Truth, CEO, Truth Medical: Yeah. You know, what we saw this year was surgeons were telling us their patients are are moving their scheduling. They're not wanting to have their surgery, you know, earlier in the year, and they're they were pushing out. Usually, that means they compress up really hard into q four. But as we got into September where we normally see a lift, we didn't see the lift we were looking for. As we end October, we didn't see a typical lift in October. And, you know, we think that tells us that that patients were continuing to defer into q four, and that was not an expectation that that that we had. We did do a a large cohort survey of surgeons, and they were telling us, and this was done in October, that year to date through October, average of that group thought their procedure volumes were down seven percent. We did a similar survey, earlier in the year, and they talked about more optimism. So more optimism going forward, but more reality when they look back. So I I think there's something there with consumer sentiment this year. It's been protracted. There's been a lot of anxiety on the consumer, and I think that plays into along with higher deductible insurance plans, I think that plays into how how patients are deciding to have the surgery for a a elective deferrable bunion procedure. We track that patient demographic. It's a very narrow defined patient demographic. And so what other companies are seeing in foot and ankle broadly or, you know, orthopedics broadly don't necessarily apply to that that demographic. Priya Sotjeba, Med Tech Analyst, UBS: Understood. Yeah. And I wanna think about, you know, pursing out outside of these headwinds, you know, some of the positive tailwinds into next year. And so I think about the new product offerings and a more comprehensive tool kit for your sales rep. Another thing that's, you know, a common trend across med tech right now is the shift to ASC. So understanding how that could potentially impact your business and what that could mean from a a growth perspective. Understanding that there might be some, you know, delayed from a patient sentiment perspective. But, you know, should that normalize, you know, what does that impact look like for you guys? John Truth, CEO, Truth Medical: Yeah. We're we're you know, bunions are are elective day surgery. They're they're not they're not inpatient. So we do surgeries in the hospital outpatient setting, and we do them in the ASCs. Our product configuration is actually really well designed for the ASC. We have sterile implant kits and very small, low cost instrumentation trays, and that works very, very well. We have a menu of different price point fixation kits and systems, so we can accommodate to different different needs there. And, you know, last but not least, the reimbursement in the ASC for the LAPIDUS fusion code basically doubled in the ASC setting as of January 1. So we were asked, is that gonna be a big tailwind for you guys? Are you gonna see a big strong uptake in in lapoplasty because of that? We were reluctant to give it too much too much bullishness at the time. But I think the big win is for the patient because going to a hospital is a little different feel than going to some of these ASCs that feel a little bit more like a like a spa and and Yeah. Warm and comfortable for the patient. So I think the big win is for the patient to be able to get a lapoplasty procedure there and, you know, more more potential to use, you know, better technology in that ASC. Priya Sotjeba, Med Tech Analyst, UBS: Do you have a percentage of, you know, how many procedures are being done in an ASC setting today? John Truth, CEO, Truth Medical: We we haven't broken that out, but we have said the more the majority is the hospital outpatient. Now there are some, you know, hospital owned freestanding centers. Some are ASCs that are hospital majority owned, and then there's just the pure private ASCs. So Priya Sotjeba, Med Tech Analyst, UBS: Do you from a sales rep perspective, you know, is there a different approach to the ASC setting versus traditional hospital setting? Or is there anything on that side that you guys are doing to kinda drive adoption in that setting? John Truth, CEO, Truth Medical: We're definitely we we have strategies to to continue to move the ball forward in the ASC. Definitely, I think most companies do these days, and we continue to work that. We haven't seen a difference in our our sales reps per se, but our national accounts team and others that work with them, you know, they're they're equipped and and working on this. Mark Harris, CFO, Truth Medical: From a and a lot of the strategy with the sales rep is to be really close to these surgeons. And surgeons commonly are performing these cases at one, two, three, four, or more, facilities. So to the extent, you know, they appreciate and understand all the value that our products are offering, it's kind of independent of the facility where they're doing the the the surgery. You know, we we believe that, those relationships and our products performance, we'll we'll just have that surgeon bring a trace rep kind of to wherever they happen to go. And it may be more in the ASC setting. We haven't seen a dramatic change in that. We've we've always had some of the ASC. We've had, like John said, more in the hospital setting, but we we just wanna be that one stop shop. If it's gonna be a bunion case, tell me where the procedure is gonna be performed, and we'll we'll be there ready for you. Priya Sotjeba, Med Tech Analyst, UBS: Got it. Yep. From a sales force perspective, do you guys feel like you're at a place, you know, confident to that this is a Salesforce that will get you to the growth that you're looking for? Is there expansion on the horizon? Just trying to think about, you know, where we at or where we are at sales rep capacity today. John Truth, CEO, Truth Medical: Yeah. We're always we're always looking for opportunities there, Priya. And I think we the thing we have noticed is since we came out with this broader platform of best in class bunion technologies, we've been getting a lot of inbound calls from highly experienced, you know, tenured, foot and ankle sales reps, from other companies across the space, and they see the opportunity here. They know Therese is is known for excellence in bunion surgery, and they see the breadth opening up. It's not just one product anymore. And so, you know, we're we're talking to them, and some we're able to bring on, some we're not, and and, we'll keep we'll keep doing so. Priya Sotjeba, Med Tech Analyst, UBS: That sounds I mean, should I become a foot and ankle sales rep? But that sounds that sounds great. Mark Harris, CFO, Truth Medical: We can help you with that, sorry, if it's if that's your goal. We can help you. Priya Sotjeba, Med Tech Analyst, UBS: Maybe a few for you, Mark, just thinking about the new product offering and and contribution to margin. You know, what should we be looking for, you know, over the next years as it becomes more of a more of a percentage of what you're selling? Mark Harris, CFO, Truth Medical: Yeah. I think, history would show that even as we've been introducing these new products, they're they're really at the same gross margin level. So they're they're very healthy gross margins. We anticipate seeing that. We've been in the high 70% gross margins. We anticipate being there. That's our goal. That's our objective. Even with introducing these new products and often what happens is is when you begin introducing them, you just don't have the economy of scale initially. So, you know, third quarter, we still had very comparable gross margins in the second quarter, and we're anticipating a slight increase in the gross margin as we come into the fourth quarter as well. So over time, we've got some great people at the company that are looking for opportunities to decrease the costs. That's always part of our, DNA is to to ensure that we're we're getting improved costs in our products and and cost reductions. And so we'll continue to look for that. And as we have more economies of scale, that that that we'll be able to to to to ensure that we have the the strong gross margins going forward. So these new products are not a headwind to us from a gross margin perspective. Priya Sotjeba, Med Tech Analyst, UBS: Okay. When you think about, you know, as you start to scale, what could the potential contribution look like? Or what's maybe a a peak goal gross margin that we could look forward to? Mark Harris, CFO, Truth Medical: So I think we've we've we haven't given a lot of information about that. But I I we we believe that we can and should be in the high 70% gross margin range. And and these new products are in no way a headwind to that. So we continue to have very innovative products. They're complementary. We're we we design them to have strong gross margins, and and that that's gonna continue to be our our plan and and outlook going forward. And and until if there are some changes, we we don't see them yet, but that's that's the objective. Priya Sotjeba, Med Tech Analyst, UBS: I got it. I think you guys mentioned on last week that the new guidance includes cash burn reduction. And can you just talk about some of those, you know, operational levers that you're pulling to kind of reduce the cost there and and how to think about that going forward as well? Mark Harris, CFO, Truth Medical: Yeah. So I think there's a couple things. One is, we we we've talked about this year with that we've been really focused on the strength of our balance sheet, reducing cash burn, and and we've we've done that. So we we've talked about, having a reduction of of about 45% or so, using 45% less cash this year versus last year. And so we we've been very proud about that. We think that's the right trend and trajectory. And so throughout the the company, we've continued to look, especially this year, for ways to reduce costs throughout the organization. We actually reported a a restructuring charge in q three, meaning that we've we've taken some steps in the third quarter to ensure that our costs are are better aligned. And we we've we've taken some some steps in in the fourth quarter, and we'll continue to look for levers to do that. So we're focused on driving the top line for all the ways that John has talked about here about with our new product portfolio and and the sales reps, all that commercial organization. We're looking for improved profitability, and we're we're looking for ways to reduce that that cash use usage as well in 2026. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. Just thinking about path to profitability. You know, of course, it'll come as you start to grow the top line, but, you know, as we parse through the balance, the remainder of the P and L, just thinking about what gets us there and what you would characterize as maybe most important to get towards profitability. Mark Harris, CFO, Truth Medical: I think the first and foremost is we're we're looking to drive the top line. We we're looking to penetrate into the market and and to get stronger relationships with our surgeon customers with this broader portfolio. So I think that's our primary focus, strengthen lapoplasty, add these new systems. Secondly, there are ways that we can improve profitability. And so we've we've started to do that. I think we've made a lot of progress this year compared to last year from from an EBITDA perspective, from a cash burn perspective, and and there are more levers that we will take and utilize as we go into 2026. So I think that's the way we're thinking about it. Drive the top line, improve that profitability throughout the the middle of the p and l, and and and that ultimately is gonna reduce the amount of cash that will be required this year or next year 2026. Priya Sotjeba, Med Tech Analyst, UBS: When we think about, capital allocation priorities, Just maybe give us a quick little refresh on, you know, debt pay down versus other other opportunities and things like that. Mark Harris, CFO, Truth Medical: So we've got a great relationship with a a lender that we have. We entered into that that debt facility back in 2022. We've got a a loan. We've got a revolver. We haven't drawn on anything since 2022, and, you know, we'll we'll continue to to think about the strength of the balance sheet as we think about that capital allocation. But, you know, we we we talked about last week, and we continue to say that we have strength in the balance sheet right now to continue to to drive the top line and and do what we need to do as a company. So, we'll continue to evaluate our our opportunities along the way, but we we feel good about the strength of the balance sheet right now. Priya Sotjeba, Med Tech Analyst, UBS: And then I might pivot back for a second and think about, you know, where we are from a market penetration perspective today and thinking about clinical data that sometimes is helpful in driving broader market penetration across all of health care. Right? Thoughts there. You know, is that something that you think is priority in terms of spend going forward to just help drive awareness and adoption? Or is there other areas that you think should be a focus to help help drive further penetration? John Truth, CEO, Truth Medical: We've we've invested pretty heavily in our line three d study to demonstrate the effectiveness and patient outcomes with lapoplasty. We just reported four and five year results on that study. The the results speak for themselves. It's a great procedure, and it has great outcomes. Our newer systems, it is in our DNA to provide clinical outcome support for them. We think it's the right thing to do for the patients, for the doctors, and for the company to continue to invest in those. But the big spend, big investment item is kinda behind us, and these are a little more, spend light that we have going forward. One thing we've we've always done and we're kinda known for is direct to consumer advertising and making sure we get the word out to patients, make the patients aware that there are new bunion treatments and new options for them. And we'll continue to to modify our our approach there and do it in a more efficient and effective way going forward, but still having that as a component to maybe help help help with the the commercial execution. Priya Sotjeba, Med Tech Analyst, UBS: Just maybe in the last five minutes here, I do wanna ask you know, we think about where the stock is today. Just maybe trying to understand maybe some of the disconnects versus share price today and what you think the fundamental growth story of Therese is just to make sure, you know, we talk about where you think we all know where we want it to be, but and to just think what the the biggest disconnect between, you know, The Street and investors versus your your view today. John Truth, CEO, Truth Medical: Well, it's it was a disappointing quarter, so I I can absolutely understand, you know, why we are who we are. And we are we're going to do things about this. Like we like we said, we're gonna get the the ramp up going with these new products and get the volumes going and get the top line reestablished. We're gonna continue to build, on our execution on our our commercial channel. And then as Mark said, we're gonna we're gonna do the right things on the P and L to make sure we got the right profile going forward. But we'll have to let let things develop over time and see where where that stock price can go. It's we've gotta go go prove some things. And, and if we do that well, then then that'll move along with it. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. I guess in that vein, when you think about the next twelve to eighteen months, like, what are the most exciting opportunities or what, you know, what you guys are most excited about for the TreeStory? John Truth, CEO, Truth Medical: I I think the most exciting thing is, this new portfolio we have, this broader portfolio, these products work so well, and they're getting such a positive reaction from surgeons. Our sales reps' enthusiasm is way up. We're seeing the volume growth, at really nice levels and and continuing there. And and we're just getting started with getting into our 3,100 customers. And then the opportunity to bring on more new customers and have them use our legacy lapoplasty and adductoplastic products too. And then continuing to launch new additional opportunities to drive more procedure volumes, more adjacent procedure growth, and letting the sales force develop along with that and and driving it forward. It's it's a really exciting time despite the, you know, the numbers and the, the feeling on on the street at the doctor level and the the the Salesforce level, the commercial team level is is very high right now. So I I think that's what that that's what's got us most excited that we're gonna see a real transformation here in Trice Medical from being a one product technology company to playing across a broader range in a very high volume segment of the market and continuing to, you know, drive increased adoption, increased penetration, and grow that share so we can become the biggest procedure share player in the bunion space. Priya Sotjeba, Med Tech Analyst, UBS: Yeah. I did just get a question from the line talking about, you know, topic du jour over the last few months has been AI and leveraging of AI in health care. And I don't know if you guys have any thoughts on, you know, broader market implementations of AI that could be a benefit to Theresa or anything internally that, you know, you guys are working on. John Truth, CEO, Truth Medical: Well, one one thing we are doing, and we didn't talk about this technology today, but we have a technology called IntelliGuide. And this is patient specific, instrumentation. So we take a patient CT scan, run it through software software manipulations, which incorporate AI, and it kicks out a, basically, diagnostic, a pre op plan for that surgeon that they can see what three-dimensional changes they're gonna make in all the bones, and then produce an actual cutting guide that is specific to that patient that the doctor can use in surgery and put it on, make their cuts, pull the bones together, and everything's corrected, you know, the way they want to. So we're using AI there, and we have another project that's gonna be an app based X-ray tool for doctors that lets them calculate the angles and measurements that they need to to make to plan their surgery. And that's another area we're using it. Mark, operationally, I I think we're we're we're not a real AI heavy company operationally. Mark Harris, CFO, Truth Medical: But but but for the but for the patients and the surgeon solutions, it's it's really those that we can have a a a patient specific diagnostic plan and cut guide instrumentation specifically for them developed through this this software. I think that's largely where where we're focused as well as as providing over time tools to surgeons that they don't that that can support their decisions in how to treat patients. So it's really those two things that we're what we're doing for the surgeon base and for ultimately our patients so that they can have great outcomes. Priya Sotjeba, Med Tech Analyst, UBS: That's super cool. And it's ten seconds left. But in terms of incorporation and workflow, like, is this something that's easy to implement? John Truth, CEO, Truth Medical: It it it is. It's it's easy to implement on the on the internal R and D side, but also workflow for the surgeon. This cuts steps. This saves time. They can do complex midfoot reconstructions that they were intimidated by. They can do complex bunion fixes and reconstructions that that are intimidating, saving steps, saving time, and increasing the accuracy. And if you're a patient, who who doesn't want something that's personalized today? So we think there's tremendous opportunity with that technology going ahead. We're the only company, at this point in time that I'm aware of that has a, you know, a midfoot correction and a bunion correction patient specific solution. And and that's pretty exciting. Priya Sotjeba, Med Tech Analyst, UBS: That's incredible. Sounds very exciting. Well, we went a little bit over, but thank you both so much for being here and and for a great conversation today. John Truth, CEO, Truth Medical: Thanks, Brian. Priya Sotjeba, Med Tech Analyst, UBS: us.
Content Reference URL	None

Publisher

Publisher Name	Investing.com (#43)
Publisher URL	https://www.investing.com
Description	None
Trust Flow Score	37
Citation Flow Score	46

Data Source

Data Source Name	NewsCatcher (#303)
Data Source Type	news
Data Source URL	https://www.newscatcherapi.com/
Description
Weight	1

DJDT

Versions

Package	Name	Version
Django		5.2.1
Python		3.11.8
coverage	Coverage	7.4.4
debug_toolbar	Debug Toolbar	4.3.0
django_extensions	Django Extensions	5.2.1
grappelli	Grappelli	4.0.2

Time

Resource usage

Resource	Value
User CPU time	46.911 msec
System CPU time	4.133 msec
Total CPU time	51.044 msec
Elapsed time	92.929 msec
Context switches	13 voluntary, 3 involuntary

Browser timing

Timing attribute	Timeline	Milliseconds since navigation start (+length)

Settings from app.settings

Setting	Value
ABSOLUTE_URL_OVERRIDES	`{}`
ADMINS	`[]`
ALLOWED_HOSTS	`['*']`
APPEND_SLASH	`True`
AUTH0_CLIENT_ID	`'********************'`
AUTH0_CLIENT_SECRET	`'********************'`
AUTH0_DOMAIN	`'********************'`
AUTHENTICATION_BACKENDS	`'********************'`
AUTH_PASSWORD_VALIDATORS	`'********************'`
AUTH_USER_MODEL	`'********************'`
BASE_DIR	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe')`
CACHES	`{'default': {'BACKEND': 'django.core.cache.backends.filebased.FileBasedCache', 'LOCATION': '/var/tmp/django_cache'}}`
CACHE_MIDDLEWARE_ALIAS	`'default'`
CACHE_MIDDLEWARE_KEY_PREFIX	`'********************'`
CACHE_MIDDLEWARE_SECONDS	`600`
CELERY_BROKER_URL	`'redis://localhost:6379'`
CELERY_RESULT_BACKEND	`'redis://localhost:6379'`
CSRF_COOKIE_AGE	`31449600`
CSRF_COOKIE_DOMAIN	`None`
CSRF_COOKIE_HTTPONLY	`False`
CSRF_COOKIE_NAME	`'csrftoken'`
CSRF_COOKIE_PATH	`'/'`
CSRF_COOKIE_SAMESITE	`'Lax'`
CSRF_COOKIE_SECURE	`False`
CSRF_FAILURE_VIEW	`'django.views.csrf.csrf_failure'`
CSRF_HEADER_NAME	`'HTTP_X_CSRFTOKEN'`
CSRF_TRUSTED_ORIGINS	`[]`
CSRF_USE_SESSIONS	`False`
DATABASES	`{'default': {'ATOMIC_REQUESTS': False, 'AUTOCOMMIT': True, 'CONN_HEALTH_CHECKS': False, 'CONN_MAX_AGE': 0, 'ENGINE': 'django.db.backends.postgresql', 'HOST': '34.125.28.12', 'NAME': 'pennyloupe', 'OPTIONS': {}, 'PASSWORD': '********************', 'PORT': '5432', 'TEST': {'CHARSET': None, 'COLLATION': None, 'MIGRATE': True, 'MIRROR': None, 'NAME': None}, 'TIME_ZONE': None, 'USER': 'pennyloupe'}}`
DATABASE_ROUTERS	`[]`
DATA_UPLOAD_MAX_MEMORY_SIZE	`2621440`
DATA_UPLOAD_MAX_NUMBER_FIELDS	`1000`
DATA_UPLOAD_MAX_NUMBER_FILES	`100`
DATETIME_FORMAT	`'N j, Y, P'`
DATETIME_INPUT_FORMATS	`['%Y-%m-%d %H:%M:%S', '%Y-%m-%d %H:%M:%S.%f', '%Y-%m-%d %H:%M', '%m/%d/%Y %H:%M:%S', '%m/%d/%Y %H:%M:%S.%f', '%m/%d/%Y %H:%M', '%m/%d/%y %H:%M:%S', '%m/%d/%y %H:%M:%S.%f', '%m/%d/%y %H:%M']`
DATE_FORMAT	`'N j, Y'`
DATE_INPUT_FORMATS	`['%Y-%m-%d', '%m/%d/%Y', '%m/%d/%y', '%b %d %Y', '%b %d, %Y', '%d %b %Y', '%d %b, %Y', '%B %d %Y', '%B %d, %Y', '%d %B %Y', '%d %B, %Y']`
DEBUG	`True`
DEBUG_PROPAGATE_EXCEPTIONS	`False`
DEBUG_TOOLBAR_CONFIG	`{'SHOW_TOOLBAR_CALLBACK': <function <lambda> at 0x7f3fcd3ef1a0>}`
DECIMAL_SEPARATOR	`'.'`
DEFAULT_AUTO_FIELD	`'django.db.models.BigAutoField'`
DEFAULT_CHARSET	`'utf-8'`
DEFAULT_EXCEPTION_REPORTER	`'django.views.debug.ExceptionReporter'`
DEFAULT_EXCEPTION_REPORTER_FILTER	`'django.views.debug.SafeExceptionReporterFilter'`
DEFAULT_FROM_EMAIL	`'webmaster@localhost'`
DEFAULT_INDEX_TABLESPACE	`''`
DEFAULT_TABLESPACE	`''`
DISALLOWED_USER_AGENTS	`[]`
EMAIL_BACKEND	`'django.core.mail.backends.smtp.EmailBackend'`
EMAIL_HOST	`'localhost'`
EMAIL_HOST_PASSWORD	`'********************'`
EMAIL_HOST_USER	`''`
EMAIL_PORT	`25`
EMAIL_SSL_CERTFILE	`None`
EMAIL_SSL_KEYFILE	`'********************'`
EMAIL_SUBJECT_PREFIX	`'[Django] '`
EMAIL_TIMEOUT	`None`
EMAIL_USE_LOCALTIME	`False`
EMAIL_USE_SSL	`False`
EMAIL_USE_TLS	`False`
FIELD_ENCRYPTION_KEY	`'********************'`
FILE_UPLOAD_DIRECTORY_PERMISSIONS	`None`
FILE_UPLOAD_HANDLERS	`['django.core.files.uploadhandler.MemoryFileUploadHandler', 'django.core.files.uploadhandler.TemporaryFileUploadHandler']`
FILE_UPLOAD_MAX_MEMORY_SIZE	`2621440`
FILE_UPLOAD_PERMISSIONS	`420`
FILE_UPLOAD_TEMP_DIR	`None`
FIRST_DAY_OF_WEEK	`0`
FIXTURE_DIRS	`[]`
FORCE_SCRIPT_NAME	`None`
FORMAT_MODULE_PATH	`None`
FORMS_URLFIELD_ASSUME_HTTPS	`False`
FORM_RENDERER	`'django.forms.renderers.DjangoTemplates'`
GCP_LOCATION	`'us-central1'`
GCP_PROJECT_ID	`'advance-honor-411011'`
GCP_PROJECT_NUMBER	`'268856636042'`
GCP_SERVICE_ACCOUNT	`'/Users/kcallahan/.config/gcloud/vector-search-user.json'`
GCP_VERTEX_BUCKET	`'pennyloupe-us-central1'`
GCP_VERTEX_INDEX_ID	`'2477861603379249152'`
GRAPPELLI_ADMIN_TITLE	`'Penny Loupe'`
GRAPPELLI_AUTOCOMPLETE_SEARCH_FIELDS	`{'auth': '********************'}`
IGNORABLE_404_URLS	`[]`
INSTALLED_APPS	`['coverage', 'grappelli', 'django.contrib.admin', 'django.contrib.auth', 'django.contrib.contenttypes', 'django.contrib.humanize', 'django.contrib.messages', 'django.contrib.postgres', 'django.contrib.sessions', 'django.contrib.staticfiles', 'django_htmx', 'app.core.apps.CoreConfig', 'django_extensions', 'debug_toolbar']`
INTERNAL_IPS	`['127.0.0.1']`
LANGUAGES	`[('en', 'English')]`
LANGUAGES_BIDI	`['he', 'ar', 'ar-dz', 'ckb', 'fa', 'ug', 'ur']`
LANGUAGE_CODE	`'en-us'`
LANGUAGE_COOKIE_AGE	`None`
LANGUAGE_COOKIE_DOMAIN	`None`
LANGUAGE_COOKIE_HTTPONLY	`False`
LANGUAGE_COOKIE_NAME	`'django_language'`
LANGUAGE_COOKIE_PATH	`'/'`
LANGUAGE_COOKIE_SAMESITE	`None`
LANGUAGE_COOKIE_SECURE	`False`
LOCALE_PATHS	`[]`
LOGGING	`{}`
LOGGING_CONFIG	`'logging.config.dictConfig'`
LOGIN_REDIRECT_URL	`'/accounts/profile/'`
LOGIN_URL	`'/accounts/login/'`
LOGOUT_REDIRECT_URL	`None`
MANAGERS	`[]`
MEDIA_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/media')`
MEDIA_URL	`'/media/'`
MESSAGE_STORAGE	`'django.contrib.messages.storage.fallback.FallbackStorage'`
MIDDLEWARE	['django.middleware.security.SecurityMiddleware', 'whitenoise.middleware.WhiteNoiseMiddleware', 'django.contrib.sessions.middleware.SessionMiddleware', 'django.middleware.cache.UpdateCacheMiddleware', 'django.middleware.common.CommonMiddleware', 'django.middleware.csrf.CsrfViewMiddleware', 'django.contrib.auth.middleware.AuthenticationMiddleware', 'django.contrib.messages.middleware.MessageMiddleware', 'django.middleware.clickjacking.XFrameOptionsMiddleware', 'django_htmx.middleware.HtmxMiddleware', 'debug_toolbar.middleware.DebugToolbarMiddleware']
MIGRATION_MODULES	`{}`
MONTH_DAY_FORMAT	`'F j'`
NUMBER_GROUPING	`0`
OPENAI_API_KEY	`'********************'`
PASSWORD_HASHERS	`'********************'`
PASSWORD_RESET_TIMEOUT	`'********************'`
POLYGON_API_KEY	`'********************'`
PREPEND_WWW	`False`
QT_API_KEY	`'********************'`
QT_APP_ID	`'13d3cbab'`
QT_PASSWORD	`'********************'`
QT_USERNAME	`'kevin+dev3@pennyloupe.com'`
ROOT_URLCONF	`'app.urls'`
SALT_KEY	`'********************'`
SCRAPER_API_KEY	`'********************'`
SECRET_KEY	`'********************'`
SECRET_KEY_FALLBACKS	`'********************'`
SECURE_CONTENT_TYPE_NOSNIFF	`True`
SECURE_CROSS_ORIGIN_OPENER_POLICY	`'same-origin'`
SECURE_HSTS_INCLUDE_SUBDOMAINS	`False`
SECURE_HSTS_PRELOAD	`False`
SECURE_HSTS_SECONDS	`0`
SECURE_PROXY_SSL_HEADER	`None`
SECURE_REDIRECT_EXEMPT	`[]`
SECURE_REFERRER_POLICY	`'same-origin'`
SECURE_SSL_HOST	`None`
SECURE_SSL_REDIRECT	`False`
SERVER_EMAIL	`'root@localhost'`
SESSION_CACHE_ALIAS	`'default'`
SESSION_COOKIE_AGE	`1209600`
SESSION_COOKIE_DOMAIN	`None`
SESSION_COOKIE_HTTPONLY	`True`
SESSION_COOKIE_NAME	`'sessionid'`
SESSION_COOKIE_PATH	`'/'`
SESSION_COOKIE_SAMESITE	`'Lax'`
SESSION_COOKIE_SECURE	`False`
SESSION_ENGINE	`'django.contrib.sessions.backends.db'`
SESSION_EXPIRE_AT_BROWSER_CLOSE	`False`
SESSION_FILE_PATH	`None`
SESSION_SAVE_EVERY_REQUEST	`False`
SESSION_SERIALIZER	`'django.contrib.sessions.serializers.JSONSerializer'`
SETTINGS_MODULE	`'app.settings'`
SHORT_DATETIME_FORMAT	`'m/d/Y P'`
SHORT_DATE_FORMAT	`'m/d/Y'`
SIGNING_BACKEND	`'django.core.signing.TimestampSigner'`
SILENCED_SYSTEM_CHECKS	`[]`
SQL_FILES_DIR	`'/mnt/disks/pennyloupe_disk/pennyloupe/app/core/sql'`
STATICFILES_DIRS	`[]`
STATICFILES_FINDERS	`['django.contrib.staticfiles.finders.FileSystemFinder', 'django.contrib.staticfiles.finders.AppDirectoriesFinder']`
STATIC_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/static')`
STATIC_URL	`'/static/'`
STORAGES	`{'default': {'BACKEND': 'django.core.files.storage.FileSystemStorage'}, 'staticfiles': {'BACKEND': 'django.contrib.staticfiles.storage.StaticFilesStorage'}}`
TEMPLATES	`[{'APP_DIRS': True, 'BACKEND': 'django.template.backends.django.DjangoTemplates', 'DIRS': ['templates'], 'OPTIONS': {'context_processors': ['django.template.context_processors.debug', 'django.template.context_processors.request', 'django.contrib.auth.context_processors.auth', 'django.contrib.messages.context_processors.messages']}}]`
TEST_NON_SERIALIZED_APPS	`[]`
TEST_RUNNER	`'django.test.runner.DiscoverRunner'`
THOUSAND_SEPARATOR	`','`
TIME_FORMAT	`'P'`
TIME_INPUT_FORMATS	`['%H:%M:%S', '%H:%M:%S.%f', '%H:%M']`
TIME_ZONE	`'UTC'`
USE_I18N	`True`
USE_THOUSAND_SEPARATOR	`False`
USE_TZ	`True`
USE_X_FORWARDED_HOST	`False`
USE_X_FORWARDED_PORT	`False`
WSGI_APPLICATION	`'app.wsgi.application'`
X_FRAME_OPTIONS	`'DENY'`
YEAR_MONTH_FORMAT	`'F Y'`

Headers

Request headers

Key	Value
Accept	/
Accept-Encoding	gzip, br, zstd, deflate
Cookie	=> see Request panel
Host	www.pennyloupe.com
User-Agent	Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)

Response headers

Key	Value
Content-Type	text/html; charset=utf-8

WSGI environ

Since the WSGI environ inherits the environment of the server, only a significant subset is shown below.

Key	Value
CONTENT_LENGTH
CONTENT_TYPE
PATH_INFO	/ticker/TMCI/content/27788752
QUERY_STRING
REMOTE_ADDR	216.73.216.158
REQUEST_METHOD	GET
SCRIPT_NAME
SERVER_NAME	pennyloupe.com
SERVER_PORT	443
SERVER_PROTOCOL	HTTP/1.1

Request

View information

View function	Arguments	Keyword arguments	URL name
`app.core.views.app.ticker_content_detail`	`()`	`{'content_id': 27788752, 'ticker': 'TMCI'}`	`ticker_content_detail`

Cookies

Variable	Value
`'csrftoken'`	`'vumZ56rmjlg8ev59T4yR03D9OX3WtyfS'`

No session data

No GET data

No POST data

SQL queries from 1 connection

default 22.79 ms (5 queries )

Query Timeline Time (ms) Action

SELECT "pl_content"."created_dt",
       "pl_content"."updated_dt",
       "pl_content"."status_id",
       "pl_content"."id",
       "pl_content"."key",
       "pl_content"."fetch_ref_id",
       "pl_content"."ticker",
       "pl_content"."publish_dt",
       "pl_content"."external_id",
       "pl_content"."published_by",
       "pl_content"."title",
       "pl_content"."summary",
       "pl_content"."tags",
       "pl_content"."url",
       "pl_content"."author",
       "pl_content"."author_reputation_score",
       "pl_content"."content_length",
       "pl_content"."parent_key",
       "pl_content"."sentiment_positive",
       "pl_content"."sentiment_negative",
       "pl_content"."sentiment_neutral",
       "pl_content"."sentiment",
       "pl_content"."sentiment_status",
       "pl_content"."relevance_score",
       "pl_content"."votes_positive",
       "pl_content"."votes_negative",
       "pl_content"."is_processing_flag",
       "pl_content"."vector_embedding_dt",
       "pl_content"."vector_id",
       "pl_content"."vector_status",
       "pl_content"."data_source_id",
       "pl_content"."parent_content_id",
       "pl_content"."publisher_id"
  FROM "pl_content"
WHERE "pl_content"."id" = 27788752
LIMIT 21SELECT ••• FROM "pl_content" WHERE "pl_content"."id" = 27788752 LIMIT 21

7.39

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2297)
  content = Content.objects.get(id=content_id)

SELECT "pl_content_content"."created_dt",
       "pl_content_content"."updated_dt",
       "pl_content_content"."status_id",
       "pl_content_content"."id",
       "pl_content_content"."key",
       "pl_content_content"."content",
       "pl_content_content"."content_ref_url",
       "pl_content_content"."content_id"
  FROM "pl_content_content"
WHERE "pl_content_content"."content_id" = 27788752
ORDER BY "pl_content_content"."id" ASC
LIMIT 1SELECT ••• FROM "pl_content_content" WHERE "pl_content_content"."content_id" = 27788752 ORDER BY "pl_content_content"."id" ASC LIMIT 1

9.59

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2303)
  content_content = ContentContent.objects.filter(details=content).first()

SELECT "pl_content_publisher"."created_dt",
       "pl_content_publisher"."updated_dt",
       "pl_content_publisher"."status_id",
       "pl_content_publisher"."id",
       "pl_content_publisher"."name",
       "pl_content_publisher"."url",
       "pl_content_publisher"."domain",
       "pl_content_publisher"."description",
       "pl_content_publisher"."weight",
       "pl_content_publisher"."trust_flow_score",
       "pl_content_publisher"."citation_flow_score"
  FROM "pl_content_publisher"
WHERE "pl_content_publisher"."id" = 43
LIMIT 21SELECT ••• FROM "pl_content_publisher" WHERE "pl_content_publisher"."id" = 43 LIMIT 21

1.25

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2306)
  publisher = content.publisher

SELECT "pl_data_source"."created_dt",
       "pl_data_source"."updated_dt",
       "pl_data_source"."status_id",
       "pl_data_source"."id",
       "pl_data_source"."name",
       "pl_data_source"."type",
       "pl_data_source"."url",
       "pl_data_source"."description",
       "pl_data_source"."weight",
       "pl_data_source"."class_name",
       "pl_data_source"."class_params_json"
  FROM "pl_data_source"
WHERE "pl_data_source"."id" = 303
LIMIT 21SELECT ••• FROM "pl_data_source" WHERE "pl_data_source"."id" = 303 LIMIT 21

3.59

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2307)
  data_source = content.data_source

SELECT COUNT(*) AS "__count"
FROM "pl_content"
WHERE "pl_content"."parent_content_id" = 27788752SELECT COUNT(*) AS "__count" FROM "pl_content" WHERE "pl_content"."parent_content_id" = 27788752

0.97

Connection: default

Transaction status: Idle

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43)
  return self.get_response(request)

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(2319)
  return render(request, "ticker_content_detail.html", context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/shortcuts.py in render(25)
  content = loader.render_to_string(template_name, context, request, using=using)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader.py in render_to_string(62)
  return template.render(context, request)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/backends/django.py in render(107)
  return self.template.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(171)
  return self._render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/test/utils.py in instrumented_test_render(114)
  return self.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader_tags.py in render(159)
  return compiled_parent._render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/test/utils.py in instrumented_test_render(114)
  return self.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/loader_tags.py in render(65)
  result = block.nodelist.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in <listcomp>(1016)
  return SafeString("".join([node.render_annotated(context) for node in self]))

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in render_annotated(977)
  return self.render(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/defaulttags.py in render(320)
  match = condition.eval(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/smartif.py in eval(61)
  return func(context, self.first, self.second)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/smartif.py in <lambda>(107)
  ">": infix(10, lambda context, x, y: x.eval(context) > y.eval(context)),

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/defaulttags.py in eval(886)
  return self.value.resolve(context, ignore_failures=True)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in resolve(722)
  obj = self.var.resolve(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in resolve(854)
  value = self._resolve_lookup(context)

/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django/template/base.py in _resolve_lookup(925)
  current = current()

27	`<td><a href="{% url 'ticker_content_detail' ticker=ticker content_id=content_detail.content.parent.id %}">{{ content_detail.content.parent.title }}</a></td>`
28	`</tr>`
29	`{% endif %}`
30	`{% if content_detail.content.children.count > 0 %}`
31	`<tr>`
32	`<th>Children</th>`
33	`<td>`
34	`<ul>`

/mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/ticker_content_detail.html

Static files (720 found, 2 used)

Static file paths

None

Static file apps

grappelli
django.contrib.admin
django_htmx
app.core
django_extensions
debug_toolbar

Static files

css/pennyloupe.css: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/css/pennyloupe.css
img/penny_loupe_logo.png: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/img/penny_loupe_logo.png

django.contrib.staticfiles.finders.AppDirectoriesFinder (720 files)

Templates (6 rendered)

Template path

templates

Templates

ticker_content_detail.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/ticker_content_detail.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fc975c900>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/TMCI/content/27788752'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb57244a0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb57244a0>>'} {'content_detail': {'content': <Content: Treace Medical at UBS Global Healthcare: Navigating Market Challenges - >, 'content_content': <ContentContent: Content ID: 35471142>, 'data_source': <DataSource: NewsCatcher>, 'publisher': <ContentPublisher: Investing.com>}, 'ticker': 'TMCI'}
base.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/base.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fc975c900>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/TMCI/content/27788752'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb57244a0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb57244a0>>'} {'content_detail': {'content': <Content: Treace Medical at UBS Global Healthcare: Navigating Market Challenges - >, 'content_content': <ContentContent: Content ID: 35471142>, 'data_source': <DataSource: NewsCatcher>, 'publisher': <ContentPublisher: Investing.com>}, 'ticker': 'TMCI'}
components/leftnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/leftnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fc975c900>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/TMCI/content/27788752'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb57244a0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb57244a0>>'} {'content_detail': {'content': <Content: Treace Medical at UBS Global Healthcare: Navigating Market Challenges - >, 'content_content': <ContentContent: Content ID: 35471142>, 'data_source': <DataSource: NewsCatcher>, 'publisher': <ContentPublisher: Investing.com>}, 'ticker': 'TMCI'} {'block': <Block Node: leftnav. Contents: [<TextNode: '\n <div'>, <IncludeNode: template=<FilterExpression '"components/leftnav.html"'>>, <TextNode: '\n </di'>]>}
components/header.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/header.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fc975c900>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/TMCI/content/27788752'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb57244a0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb57244a0>>'} {'content_detail': {'content': <Content: Treace Medical at UBS Global Healthcare: Navigating Market Challenges - >, 'content_content': <ContentContent: Content ID: 35471142>, 'data_source': <DataSource: NewsCatcher>, 'publisher': <ContentPublisher: Investing.com>}, 'ticker': 'TMCI'} {'block': <Block Node: header. Contents: [<TextNode: '\n\n '>, <IncludeNode: template=<FilterExpression '"components/header.html"'>>, <TextNode: '\n\n '>]>}
components/ticker_subnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/components/ticker_subnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fc975c900>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/TMCI/content/27788752'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb57244a0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb57244a0>>'} {'content_detail': {'content': <Content: Treace Medical at UBS Global Healthcare: Navigating Market Challenges - >, 'content_content': <ContentContent: Content ID: 35471142>, 'data_source': <DataSource: NewsCatcher>, 'publisher': <ContentPublisher: Investing.com>}, 'ticker': 'TMCI'} {'block': <Block Node: content. Contents: [<TextNode: '\n\n <div class="uk-flex'>, <IncludeNode: template=<FilterExpression '"components/ticker_subnav.html"'>>, <TextNode: '\n <!-- /SUB NAV--'>, <Variable Node: content_detail.content.title>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <IfNode>, <TextNode: '\n '>, <Variable Node: content_detail.content.id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.external_id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.author>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.publish_dt>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.summary>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.tags>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <Variable Node: content_detail.content.sentiment_negative>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '<br/>\n '>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb618c5d0>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb618e710>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7f3fb617b150>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.relevance_score>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <IfNode>, <TextNode: '\n <li clas'>, <Variable Node: content_detail.data_source.name>, <TextNode: '\n '>, <Variable Node: content_detail.data_source.id>, <TextNode: ')\n '>, <Variable Node: content_detail.data_source.type>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.url>, <TextNode: '" target="_blank">'>, <Variable Node: content_detail.data_source.url>, <TextNode: '</a></td>\n '>, <Variable Node: content_detail.data_source.description>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.weight>, <TextNode: '</td>\n '>]>} {'ticker': 'TMCI'}
components/footer.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/footer.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7f3fc975c900>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/TMCI/content/27788752'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb57244a0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7f3fb57244a0>>'} {'content_detail': {'content': <Content: Treace Medical at UBS Global Healthcare: Navigating Market Challenges - >, 'content_content': <ContentContent: Content ID: 35471142>, 'data_source': <DataSource: NewsCatcher>, 'publisher': <ContentPublisher: Investing.com>}, 'ticker': 'TMCI'} {'block': <Block Node: footer. Contents: [<TextNode: '\n '>, <IncludeNode: template=<FilterExpression '"components/footer.html"'>>, <TextNode: '\n '>]>}

Context processors

django.template.context_processors.csrf: Toggle context
{'csrf_token': <SimpleLazyObject: <function csrf.<locals>._get_val at 0x7f3fc975c900>>}
django.template.context_processors.debug: Toggle context
{}
django.template.context_processors.request: Toggle context
{'request': <WSGIRequest: GET '/ticker/TMCI/content/27788752'>}
django.contrib.auth.context_processors.auth: Toggle context
{'user': <SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb57244a0>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7f3fb57244a0>>)}
django.contrib.messages.context_processors.messages: Toggle context
{'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/TMCI/content/27788752'>>, 'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30, 'ERROR': 40}}

Cache calls from 1 backend

Summary

Total calls	Total time	Cache hits	Cache misses
0	0 ms	0	0

Commands

add	get	set	get_or_set	touch	delete	clear	get_many	set_many	delete_many	has_key	incr	decr	incr_version	decr_version
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Signals

Signal	Receivers
class_prepared
connection_created	register_type_handlers
got_request_exception
m2m_changed
post_delete
post_init
post_migrate	create_permissions, create_contenttypes
post_save	create_initial_trade_position
pre_delete
pre_init
pre_migrate	inject_rename_contenttypes_operations
pre_save
request_finished	close_old_connections, close_caches, reset_urlconf
request_started	reset_queries, close_old_connections
setting_changed	reset_cache, clear_cache_handlers, update_installed_apps, update_connections_time_zone, clear_routers_cache, reset_template_engines, storages_changed, clear_serializers_cache, language_changed, localize_settings_changed, complex_setting_changed, root_urlconf_changed, static_storage_changed, static_finders_changed, form_renderer_changed, auth_password_validators_changed, user_model_swapped, update_toolbar_config, reset_hashers, Options.setting_changed, update_level_tags, uninstall_if_needed, clear_caches, StaticFilesStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties

Path	Location
.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/.DS_Store
grappelli/.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/.DS_Store
grappelli/js/grappelli.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.js
grappelli/js/jquery.grp_related_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_m2m.js
grappelli/js/jquery.grp_autocomplete_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_fk.js
grappelli/js/jquery.grp_autocomplete_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_generic.js
grappelli/js/jquery.grp_timepicker.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_timepicker.js
grappelli/js/jquery.grp_collapsible_group.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible_group.js
grappelli/js/jquery.grp_related_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_generic.js
grappelli/js/jquery.grp_related_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_fk.js
grappelli/js/jquery.grp_collapsible.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible.js
grappelli/js/grappelli.min.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.min.js
grappelli/js/jquery.grp_autocomplete_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_m2m.js
grappelli/js/jquery.grp_inline.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_inline.js
grappelli/images/spritesheet-1694777276.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/spritesheet-1694777276.png
grappelli/images/backgrounds/loading-small.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/loading-small.gif
grappelli/images/backgrounds/changelist-results.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/changelist-results.png
grappelli/images/backgrounds/ui-sortable-placeholder.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/ui-sortable-placeholder.png
grappelli/images/backgrounds/nav-grabber.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/nav-grabber.gif
grappelli/images/backgrounds/messagelist.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/messagelist.png
grappelli/images/icons/ui-datepicker-next.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/ui-datepicker-next.png
grappelli/images/icons/link-external-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-external-small_hover.png
grappelli/images/icons/tools-arrow-up-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-arrow-up-handler_hover.png
grappelli/images/icons/date-hierarchy-back.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/date-hierarchy-back.png
grappelli/images/icons/tools-delete-handler-predelete.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler-predelete.png
grappelli/images/icons/breadcrumbs-rtl.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs-rtl.png
grappelli/images/icons/datepicker_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/datepicker_hover.png
grappelli/images/icons/tools-trash-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-trash-handler_hover.png
grappelli/images/icons/selector-add-m2m-vertical_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/selector-add-m2m-vertical_hover.png
grappelli/images/icons/tools-related-remove-handler-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small_hover.png
grappelli/images/icons/sorted-descending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-descending.png
grappelli/images/icons/breadcrumbs_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs_hover.png
grappelli/images/icons/tools-viewsite-link_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-viewsite-link_hover.png
grappelli/images/icons/object-tools-add-link.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/object-tools-add-link.png
grappelli/images/icons/tools-related-edit-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-edit-handler-small-disabled.png
grappelli/images/icons/tools-related-remove-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small-disabled.png
grappelli/images/icons/sorted-ascending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-ascending.png
grappelli/images/icons/link-internal-rtl-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-internal-rtl-small_hover.png
grappelli/images/icons/pulldown-handler_selected.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/pulldown-handler_selected.png
grappelli/images/icons/tools-delete-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler_hover.png